Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma
ConclusionsOur study provides the first report of the severe, early reactivation of an inactive HBsAg carrier after CAR T cell therapy in DLBCL.Trial registrationChiCTR-OPN-16008526.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Bilirubin | Cancer | Cancer & Oncology | Chemotherapy | Hematology | Hepatitis | Hepatitis B | Immunotherapy | Jaundice | Liver | Lymphoma | Study | Urology & Nephrology